Allan EK - Search Results

1

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.

Jørgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, Holyoake TL. Jørgensen HG, et al. Among authors: allan ek. Clin Cancer Res. 2006 Jan 15;12(2):626-33. doi: 10.1158/1078-0432.CCR-05-0429. Clin Cancer Res. 2006. PMID: 16428509

2

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.

Jørgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA, Mountford JC, Eaves CJ, Holyoake TL. Jørgensen HG, et al. Among authors: allan ek. Leukemia. 2005 Jul;19(7):1184-91. doi: 10.1038/sj.leu.2403785. Leukemia. 2005. PMID: 15889158

3

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Jørgensen HG, et al. Among authors: allan ek. Blood. 2002 Jan 15;99(2):713-5. doi: 10.1182/blood.v99.2.713. Blood. 2002. PMID: 11781261 Free article.

4

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.

Jørgensen HG, Allan EK, Mountford JC, Richmond L, Harrison S, Elliott MA, Holyoake TL. Jørgensen HG, et al. Among authors: allan ek. Exp Hematol. 2005 Oct;33(10):1140-6. doi: 10.1016/j.exphem.2005.05.020. Exp Hematol. 2005. PMID: 16219536 Free article.

5

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Copland M, et al. Among authors: allan ek. Blood. 2006 Jun 1;107(11):4532-9. doi: 10.1182/blood-2005-07-2947. Epub 2006 Feb 9. Blood. 2006. PMID: 16469872 Free article.

6

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Jørgensen HG, et al. Among authors: allan ek. Blood. 2007 May 1;109(9):4016-9. doi: 10.1182/blood-2006-11-057521. Epub 2007 Jan 9. Blood. 2007. PMID: 17213283 Free article. Clinical Trial.

7

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL. Copland M, et al. Among authors: allan ek. Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21. Blood. 2008. PMID: 18156496 Free article.

8

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Graham SM, et al. Blood. 2002 Jan 1;99(1):319-25. doi: 10.1182/blood.v99.1.319. Blood. 2002. PMID: 11756187 Free article.

9

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.

Allan EK, Holyoake TL, Craig AR, Jørgensen HG. Allan EK, et al. Leukemia. 2011 Jun;25(6):985-94. doi: 10.1038/leu.2011.55. Epub 2011 Apr 5. Leukemia. 2011. PMID: 21468038 Free article.

10

Fluorescence in situ hybridization for BCR-ABL.

Drummond MW, Allan EK, Pearce A, Holyoake TL. Drummond MW, et al. Among authors: allan ek. Methods Mol Med. 2004;97:103-16. doi: 10.1385/1-59259-760-2:103. Methods Mol Med. 2004. PMID: 15064488 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters